AMGN Stock Price Today (October 2026) — Amgen Inc. Analysis & Key Metrics 2026-10-07
Amgen Inc. (AMGN) is trading at $413.08, up 2.60% today (as of October 2026). The stock continues to show mixed signals with a short-term dip within a broader uptrend, attracting attention from investors looking for Healthcare growth opportunities.
- According to consensus analyst estimates, the 1-year price target is $390.94 (5.4% downside).
- Volatility is moderate (25.29% annualized), implying notable price swings for short-term traders.
- The fundamental picture, based on the latest financial filings, is nuanced: solid revenue growth (9.50% YoY) alongside competitive pressures in the Drug Manufacturers - General space.
AMGN Stock Analysis: Key Metrics & Valuation (October 2026)
Concise, actionable data for investors
Amgen Inc. - Historical Price & Volume
- Price
- Volume
- Latest price
Market Cap
Enterprise Value: $266.64B
P/E Ratio
Forward P/E: 17.62
Revenue Growth
Year over Year
Analyst Target
-5.4% downside from target
Key Investor Questions About AMGN
What investors need to know before buying
Based on current market data, AMGN presents a neutral technical setup with caution warranted fundamentals.
- Technicals say: Neutral (RSI 56.18)
- Fundamentals say: Caution warranted (high leverage concerns)
AMGN's growth trajectory depends on its ability to expand within the Drug Manufacturers - General sector while managing margin pressures.
- Future growth will depend on performance in core Drug Manufacturers - General operations.
- The ability to manage competitive pressures will be crucial for sustained growth.
The primary risks for AMGN investors include debt exposure and competitive dynamics in the Drug Manufacturers - General industry.
- $57.30B in debt could be a headwind in a high-rate environment.
- Fierce competition from established players in Drug Manufacturers - General.
52-Week Trading Range
Over the past year, AMGN stock traded between $288.00 and $447.03 and currently trades in the middle of that range. Big swings are likely unless a major catalyst emerges.
Volatility & Risk Profile
With 25.29% annualized volatility and β=0.55, the stock exhibits low sensitivity to market moves—making AMGN suitable for investors comfortable with active risk management.
Institutional & Insider Ownership
High institutional ownership with low short interest suggests steadier hands and low immediate risk.
Analyst Sentiment & Price Targets
Latest News & Headlines
Recent headlines and coverage
Amgen’s Deerfield office campus sold to Mesirow for $151M in sale-leaseback deal
Mesirow CEO Richard S. Price with 1 Horizon Way in Deerfield (Getty, Mesirow, Google Maps)An entity tied to Chicago financial services firm Mesirow bought the Amgen office complex in Deerfield in a sale-leaseback deal for $151 million. The deal for the property, which spans 660,000 square feet of office space in three buildings at 1 Horizon Way along I-294 in suburban Deerfield, is rare for a site of its 70-acre size, according to Crain’s. The suburbs still suffer from high vacancy rates and sha
Amgen (AMGN) Rises Higher Than Market: Key Facts
In the latest trading session, Amgen (AMGN) closed at $414.61, marking a +2.11% move from the previous day.
Investors Heavily Search Amgen Inc. (AMGN): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to Amgen (AMGN). This makes it worthwhile to examine what the stock has in store.
How Investors Are Reacting To Veeva Systems (VEEV) Expanding Agentic AI And Winning New Pharma Clients
In recent days, Veeva Systems has rolled out new AI-powered tools such as Veeva Study Builder Agent and Veeva Falcon Router, while announcing major customer wins including Oxford Biomedica adopting Veeva Quality Cloud and Amgen planning a global deployment of Veeva Vault CRM. Together, these developments highlight Veeva’s push to embed agentic AI across clinical, safety, quality, and commercial workflows, reinforcing its role as an end-to-end software partner for life sciences...
Winners And Losers Of Q2: Amgen (NASDAQ:AMGN) Vs The Rest Of The Therapeutics Stocks
As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q2. Today, we are looking at therapeutics stocks, starting with Amgen (NASDAQ:AMGN).
Amgen (AMGN) Is Up 7.9% After Positive Phase 3 Dazodalibep Data in Systemic Sjögren’s Disease
Amgen recently reported positive topline Phase 3 OASIZ 301 results for dazodalibep in adults with moderate-to-severe systemic Sjögren’s disease, showing statistically significant and clinically meaningful ESSDAI improvements sustained through Week 48 with generally mild to moderate side effects. Because there are currently no approved disease‑modifying therapies for persistent systemic Sjögren’s, this potential first‑in‑class CD40L antagonist could address an important unmet treatment...
Amgen Boasts Success In Sjogren's; Shares Charge Ahead
Amgen stock bounded above its 50-day line Tuesday after publishing promising results for its experimental Sjogren's treatment.
Amgen reports a Phase 3 win with Sjögren’s drug candidate
Dazodalibep, acquired in Amgen’s big buyout of Horizon Therapeutics, succeeded in the first of two late-stage trials against the tough-to-treat autoimmune disorder.
AMGN Jumps After Win In Sjögren’s Disease Trial As Citi Flags ‘Open Questions’
In a trial in patients with Sjögren’s disease, Amgen’s dazodalibep produced a statistically significant and clinically meaningful improvement on a standard score of how the disease affects organs and systems.
Amgen (AMGN) Posted Positive Phase 3 Results In Sjögren's Disease
Amgen (NasdaqGS:AMGN) reported positive Phase 3 trial results for dazodalibep in Sjögren's disease, targeting a major unmet autoimmune need. The company described dazodalibep as a potential first-in-class therapy, following successful outcomes in patients with Sjögren's disease. Amgen received an FDA label update for IMDELLTRA in extensive-stage small cell lung cancer, reducing recommended patient monitoring times. The dazodalibep Phase 3 success and IMDELLTRA monitoring change both reshape...
Explore More Analysis for AMGN
Additional research, tools, and technical breakdowns
Stock Analyzer Report
Deep-dive automated research and stock rating report.
DCF Fair Value Calculator
Discounted cash flow model and intrinsic value projection.
AI Price Predictions
Multi-scenario price predictions and consensus targets.
Insider Activity Tracker
Track buying/selling behavior of corporate insiders.
Earnings Calendar
Track upcoming and historical corporate earnings reports.
Market Insights & Research
Read the latest analysis articles and expert research.
Earnings snapshot
Next report Nov 3, 2026 (after the close)
Frequently Asked Questions
Common investor questions about Amgen Inc.
Amgen Inc. (AMGN) is currently trading at $413.08. The RSI (14-day) is at 56.2, indicating neutral territory. Wall Street analysts have a consensus "hold" recommendation. The mean analyst price target of $390.94 implies 5.4% downside from current levels. Volatility is moderate at 25.3% annualized, meaning price movements are relatively contained. Investors should consider their risk tolerance, investment horizon, and portfolio diversification before making a decision.
Based on current valuation metrics for Amgen Inc. (AMGN): The trailing P/E ratio is 23.71, which is in line with broader market averages. The forward P/E is 17.62, lower than the trailing P/E, suggesting analysts expect earnings improvement. The PEG ratio is 2.29, above 2.0, suggesting the stock may be overvalued relative to its expected growth. Price-to-Book is 17.65. Price-to-Sales is 5.41. Valuation should be compared to Drug Manufacturers - General industry peers for context, as different sectors trade at different multiples.
Based on 29 analysts covering AMGN, the consensus price target is $390.94. This represents a 5.4% downside from the current price of $413.08. The range spans from a low target of $225.00 to a high target of $500.00, reflecting varying levels of optimism among analysts. The consensus recommendation is "hold". Note: Analyst price targets are forward-looking estimates and not guarantees of future performance.
Yes, Amgen Inc. (AMGN) pays a dividend with a current yield of approximately 2.44%. The annualized dividend rate is $9.80 per share. The payout ratio is 60.9%, which is moderate and suggests adequate earnings coverage for the dividend. The most recent ex-dividend date was Aug 21, 2026.
Key risks for Amgen Inc. (AMGN) investors include: 1. Moderate volatility (25.3% annualized)—price swings are notable. 2. Elevated debt levels (debt-to-equity of 4.90x) which could pressure margins in a rising rate environment. 3. Broader market and macroeconomic risks (interest rates, inflation, geopolitical events). 4. Drug Manufacturers - General sector-specific competitive pressures. Investors should diversify and consider their risk tolerance before investing.
Here is Amgen Inc.'s (AMGN) current debt and financial health profile: Total debt stands at $57.30B. The debt-to-equity ratio is 4.90x, which is high and could pose financial risk if earnings decline or borrowing costs increase. The current ratio is 1.37, indicating adequate short-term liquidity. The quick ratio is 0.95. The company holds $13.99B in cash and equivalents. Free cash flow is positive at $8.65B, providing a cushion for debt servicing and shareholder returns.